Skip to main content
Download PDF

High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration

Critical Care volume 28, Article number: 270 (2024) Cite this article

Abstract

Background

Sepsis presents a challenge due to its complex immune responses, where balance between inflammation and anti-inflammation is critical for survival. Glucocorticoid-induced leucine zipper (GILZ) is key protein in achieving this balance, suppressing inflammation and mediating glucocorticoid response. This study aims to investigate GILZ transcript variants in sepsis patients and explore their potential for patient stratification and optimizing glucocorticoid therapy.

Methods

Sepsis patients meeting the criteria outlined in Sepsis-3 were enrolled, and RNA was isolated from whole blood samples. Quantitative mRNA expression of GILZ transcript variants in both sepsis patient samples (n = 121) and the monocytic U937 cell line (n = 3), treated with hydrocortisone and lipopolysaccharides, was assessed using quantitative PCR (qPCR).

Results

Elevated expression of GILZ transcript variant 1 (GILZ TV 1) serves as a marker for heightened 30-day mortality in septic patients. Increased levels of GILZ TV 1 within the initial day of sepsis onset are associated with a 2.2-[95% CI 1.2–4.3] fold rise in mortality, escalating to an 8.5-[95% CI 2.0–36.4] fold increase by day eight. GILZ TV1 expression is enhanced by glucocorticoids in cell culture but remains unaffected by inflammatory stimuli such as LPS. In septic patients, GILZ TV 1 expression increases over the course of sepsis and in response to hydrocortisone treatment. Furthermore, a high expression ratio of transcript variant 1 relative to all GILZ mRNA TVs correlates with a 2.3-fold higher mortality rate in patients receiving hydrocortisone treatment.

Conclusion

High expression of GILZ TV 1 is associated with a higher 30-day sepsis mortality rate. Moreover, a high expression ratio of GILZ TV 1 relative to all GILZ transcript variants is a parameter for identifying patient subgroups in which hydrocortisone may be contraindicated.

Introduction

Sepsis is a multifactorial immunologic syndrome, in which the inflammatory and the anti-inflammatory immune response occur simultaneously and excessively [1]. To achieve higher survival rates, it seems important, that these two reactions remain in a balanced relationship to each other [2]. Both pro-inflammatory and anti-inflammatory overreaction of the immune system, as well as the disproportionate relationship between them, are associated with increased mortality [3]. Therefore, the unbalanced ratio of pro- and anti-inflammation is remaining a main challenge during sepsis [4]. However, it is unknown what ratio is beneficial for each individual patient, how is this ratio changed in specific stages of the sepsis course, such as the early and the late disease phase, as well as the regulatory mechanisms for a balanced immune response [5]. Therefore, it is necessary to investigate the regulatory mechanisms, which are responsible for a fine-tuned and coordinated relationship between pro- and anti-inflammation [6]. The glucocorticoid-induced leucine zipper (GILZ) can potentially act as key protein for attaining a balanced immune response [7]. GILZ is a significant player in the glucocorticoid system [8]. The glucocorticoid system is an important regulatory framework with significant clinical relevance and regulates the pro- and anti-inflammatory response. In addition, GILZ, a TSC22D3 gene product, is identified as a promising protein for sepsis survival in a mouse model [9, 10]. The importance of GILZ in sepsis can be attributed to its ability to suppress inflammation in the innate and adaptive part of the immune system [11, 12]. Furthermore, GILZ takes control over the endogenous glucocorticoid secretion via negative feedback loop mechanism, given that the inflammation process triggers the activation of the glucocorticoid system [13]. Thus, by impacting on the endogenous cortisol synthesis in sepsis, GILZ changes the necessity for treatment with exogenous glucocorticoids. Previous studies have identified GILZ transcript variants (TVs) and their biological activity; nevertheless, the impact of these variants on sepsis survival in humans has not been further investigated [14,15,16]. For this reason, the intent of the present research was to assess the GILZ transcript profile in a cohort of sepsis patients. In addition, as a potential regulatory mechanism, the expression of the TVs was examined in cell culture after incubation with hydrocortisone, dexamethasone, or lipopolysaccharides (LPS), in order to analyse whether glucocorticoids or an inflammatory trigger can influence the GILZ TV expression. Finally, we examined whether the expression of GILZ TVs can be utilized for the stratification of patients who would benefit from glucocorticoid therapy. Therefore, the main hypotheses of the current study are as follows: 1) the expression of specific GILZ TVs is differentially regulated during sepsis, 2) glucocorticoids and not inflammation upregulate GILZ expression and 3) GILZ mRNA expression alterations can be utilized for identifying patient subgroups with differing sepsis mortality.

Materials and methods

Patient recruitment

Sepsis patients were recruited from SepsisDataNet.NRW (NRW-North Rhine-Westphalia, Germany) The NRW project was approved by the Ethics Committee of the Medical Faculty of the Ruhr University of Bochum (No. 18–6606-BR), as well as by the Ethics Committees of the University of Münster (No. 2017–513-b-S) and the University of Bonn. All patients fulfilled criteria according to the Sepsis-3 definition [17]. Patient studies were performed at the hospital Knappschaftskrankenhaus Bochum GmbH (University of Bochum), hospital St. Elisabeth Gruppe GmbH and hospital Herford (University of Bochum), as well as in the clinics for anesthesiology (University of Münster and University of Bonn), following the SepsisDataNet.NRW program (German clinical trial registry: DRKS00018871) [18,19,20]. The patients were recruited in the period between March 1, 2018, and December 31, 2019 in the ICUs of seven German university clinics. In this project, peripheral blood was obtained on day one, within the first 36 h after sepsis diagnosis, and on day four and on day eight. Characteristics of the these patients can be found in Table 1. In addition, a postoperative control cohort was included, which consisted of post-operative patients, which did not develop sepsis in the post-operative course. Characteristics of the control patients can be found in Table 2. Written informed consent was given by all patients or their legal representatives.

Table 1 Baseline characteristics of sepsis patients
Full size table
Table 2 Baseline characteristics of control patients
Full size table

Blood sample collection, preparation, and storage

Whole blood was taken from patients immediately processed [17]. For immediate isolation of RNA, an RNA Blood Tube (Applied Biosystems, Life Technologies, Darmstadt, Germany) was used obtained from septic patients on day one and eight. Not all patients had samples available at both time points (Supplementary Table 5). RNA was extracted from whole blood samples with a Tempus™ Spin RNA (Applied Biosystems) kit in accordance with the manufacturer’s instructions. A high-capacity cDNA reverse transcription kit (Applied Biosystems) was used for reverse transcription of the messenger RNA (mRNA) into complementary DNA (cDNA). RNA sample aliquots were stored at −80 °C.

GILZ-mRNA quantification

The gene expression analysis was performed with quantitative polymerase chain reaction (qPCR) in duplicate using GoTaq® qPCR Master Mix (Promega, Madison, WI, USA) or ZymoTaq qPCR Premix (Zymo Research, Irvine, CA, USA) for the related primers (Eurofins Scientific SE, Hamburg, Germany) (Supplementary Table 1) on a CFX Connect Real-Time System (Bio-Rad Laboratories, Hercules, CA, USA). For GILZ (TSC22D3) TVs No. 1–5, the corresponding GoTaq® qPCR Master Mix or ZymoTaq qPCR Premix was used (Supplementary Table 1). A total of 25 µL of reaction mixture (containing 12.5 µL of GoTaq qPCR Master Mix or ZymoTaq qPCR Premix, 2.5 µL of cDNA (10 ng/µL), 1 µL of forward primer, 1 µL of reverse primer, and 8 µL of nuclease-free H₂O (Promega, Madison, WI, USA)) was added to a 96-well reaction plate (Sarstedt, Nümbrecht, Germany). q-PCR amplification was completed using the following protocols: GoTaq qPCR® Master Mix—a denaturation cycle at 95 °C for 2 min, followed by 40 cycles of 95 °C for 30 s and the respective annealing temperature for 30; ZymoTaq qPCR Premix—a denaturation cycle at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, accompanied by the corresponding annealing temperature for 30 s and an extension step at 72 °C, with a final extension at 72 °C for 7 min. The relative GILZ-mRNA expression was adjusted to the expression of the reference gene β-actin (Integraed DNA Technologies, Coralvillem, IA, USA) and, if not otherwise mentioned, was computed using the 2−∆CT method.

Quantification of cytokines in serum

Serum samples collected upon admission were analyzed for thirteen cytokines. The LEGENDPlex™ Human Inflammation Panel 1 (BioLegend, San Diego, CA, USA) was employed following the manufacturer’s protocol. Briefly, 25 µL of serum was incubated with LEGENDPlex™ beads for antigen capture, followed by washing and incubation with detection antibodies. Fluorescence intensity was then measured using a flow cytometer (Canto II, BD Biosciences, San Jose, CA, USA). Cytokine concentrations falling below the lower limit of detection (LOD) were recorded as 0 pg/mL, while concentrations exceeding the upper LOD were recorded as the LOD value itself.

Cell culture experiments with U937 cells

We used the U937 cell line to test the effect of hydrocortisone and LPS on TSC22D3 transcript variant expression. The U937 cells were purchased from DSMZ (Leipzig, Germany). The cells were cultured in RPMI 1640 medium (PAN-Biotech, Aidenbach, Germany) supplemented with heat-inactivated 10% FCS (PAN-Biotech)), penicillin (100 U/ml) and streptomycin (100 μg/ml) (both Thermo Fisher Scientific, Bremerhaven, Germany). The cells were maintained in a humidified atmosphere at 37 °C with 5% CO2 and were split three times a week to maintain a cell density of approximately 106 cells/ml. Cells from early passages (< 25) were used for all tests, seeded in 6-well plates and stimulated with 10−6 M hydrocortisone, 10−6 M dexamethasone, 10 µg/ml LPS or 100 ng/ml LPS (all from Sigma‒Aldrich, Taufkirchen, Germany) or left unstimulated (control).

Cell stimulation was stopped after 2 h, 6 h or 24 h of cell lysis, and RNA was isolated with an RNeasy Mini Kit (Qiagen, Hilden, Germany). The purified mRNA samples were reverse transcribed into complementary DNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems).

Statistical analyses

The characteristics of the recruited patients are given as numbers and percentages for categorical variables, means and standard deviations (± SD), or medians with corresponding interquartile ranges for continuous variables. After generating the ROC curve and computing the Youden index, a cutoff value was determined for each of the presented TSC22D3 transcript variants and for the computed ratio (ΔCt GILZ TV 1 relative to all transcript variants) as the point of best discrimination between sepsis survivors and non-survivors. The survival rate of the septic patients, divided by the cutoff value for the corresponding TSC22D3 transcript variant or TV 1 expression ratio, was estimated by Kaplan‒Meier survival curves. To determine the statistical significance of the observed survival effect, a log rank test was performed. Hazard ratios with corresponding 95% confidence intervals (HRs) were determined using univariate Cox regression analysis or multivariate Cox regression to estimate the independence of each TSC22D3-mRNA transcript variant on survival and to assess the associations between covariates and mortality. All assessed variables were tested for a normal distribution with the Shapiro‒Wilk test. For comparisons of continuous variables, an unpaired t test, a Mann‒Whitney-U test or one-way ANOVA was used. P values lower than 0.05 were considered to indicate statistical significance. All the statistical calculations were performed with SPSS Statistics (Version 28.0.0.0, IBM, Armonk, NY, USA), and the graphics were created with GraphPad Prism 8 (Graph-Pad, San Diego, CA, USA).

Results

Patient characteristics

Samples from 121 patients diagnosed with sepsis were analyzed. Most septic patients were male (57.9%), the median sequential organ failure assessment (SOFA) score was 8, the 30-day mortality was 44.6%, and the main focus of infection was the lower respiratory tract (Table 1).

GILZ transcript variant expression in patients during sepsis

In a first step, we examined whether GILZ TV expression could be relevant in sepsis. We measured the expression of all GILZ TV on days one and eight after sepsis diagnosis (Fig. 1A–E). GILZ mRNA expression increased in transcript variants 1,3, and 5 from day one to day eight. The expression of GILZ TV 1 (p = 0.0072, Fig. 1A) increased nearly fivefold, and the expression of GILZ TV 5 more than doubled (p = 0.0014; Fig. 1E). No significant increase could be seen in transcript variant 2 and 4 (Fig. 1B, D). In the postoperative control cohort GILZ expression differed from septic patients. GILZ mRNA level seemed to be reduced in septic patients in transcript variants 1, 2, 3, where it was increased at the onset of sepsis in transcript variants 4 and 5 (Fig. 1A–E). In a next step we examined the impact of GILZ transcript variant expression on sepsis survival. After plotting the receiver operating characteristic curve and calculating the area under the curve (AUC) for each GILZ TV (Supplementary Table 2), we focused our investigations on GILZ TV 1: The classification threshold models for this TV had the best performance in survival analysis (AUC: 0.628 for day 1 and AUC: 0.783 for day 8) with a p value lower than 0.05. The selected threshold values were for GILZ TV 1, Day 1—HR = 2.2, (CI:1.1,4.2), p = 0.016, Cut-off = 2.543*10−6; and for GILZ TV 1, Day 8—HR = 8.5, (CI:1,9,36,38), p = 0,004, Cut-off = 7.604*10−6.

Fig. 1
figure 1

Quantitative GILZ-mRNA expression of TV 1–5 in patients one and eight days after sepsis diagnosis. The expression was normalized to that of the housekeeping gene ß-actin (ACTB) using the 2 − ∆CT formula. day one, n = 105; day eight, n = 53; *p = 0.0121; **p = 0.004; ***p = 0.0007; ****p < 0.0001

Full size image

Survival analysis of sepsis patients expressing GILZ transcript variant 1 on days one and eight after sepsis onset

After performing ROC analysis and computing the Youden index for identifying the best point of discrimination between sepsis survivors and non-survivors, Kaplan–Meier (K-M) analysis was performed. K-M curves revealed the impact of GILZ TV1 on the 30-day survival rate (Fig. 2A‒B). High mRNA expression of GILZ TV 1 on day one and day eight (red lines) is associated with increased sepsis mortality. There was a 2.2-fold increase in sepsis mortality in patients with high levels of GILZ TV 1 on day one (p = 0.015; 95% CI 1.1–4.2, Cut-off = 2.543*10−6, Fig. 2A), and there was an 8.5-fold increase in sepsis mortality in those with high levels of GILZ TV 1 on day eight (p = 0.004; 95% CI 1.98–36.28, Cut-off = 7.604*10−6, Fig. 2B).

Fig. 2
figure 2

K-M curves showing the 30-day survival rate of sepsis patients. A Patients with low (blue) or high (red) GILZ-mRNA TV 1 expression on the day of sepsis onset (HR = 2.2, p = 0.016, 95% CI 1.1–4.2). B Patients with low (blue) or high (red) GILZ-mRNA TV 1 expression on day eight after sepsis onset (HR = 8.5, p = 0.004, 95% CI 1.98–36.28). Numbers in brackets represent the number of dead patients in relation to total tested patient number

Full size image

High expression of GILZ TV 1 on day one was a risk factor for 30-day mortality (HR = 2.183; 95% CI (1.16–4.01); p = 0.015) and patients did not differ in SOFA-score or other characteristics (Supplementary Table 3). In a multivariate Cox regression high GILZ TV 1 expression on day one was no longer an independent risk factor (Supplementary Table 4). On the other side, high GILZ TV 1 expression on day eight was even a stronger risk factor for sepsis mortality (HR = 10.569, p = 0.027; 95% CI 1.309–85.309), independent of SOFA score on day, age, sex and hydrocortisone treatment according to the multivariate Cox regression model (Table 3).

Table 3 Univariate and multivariate cox regression for GILZ TV 1, day eight
Full size table

Impact of hydrocortisone and LPS on GILZ transcript variant expression in the U937 cell line

In a second step, we investigated possible regulatory mechanisms for GILZ-mRNA expression in septic patients. We stimulated U937 cells with hydrocortisone (10−6 M), dexamethasone (10−6 M) and LPS (10 µg/ml and 100 ng/ml) for 2 h, 6 h and 24 h. Compared to the control sample, incubation with hydrocortisone for 6 h and 24 h resulted in higher expression of GILZ TV 1 (*p = 0.0309, **p = 0.003, n = 3; Fig. 3A -). Further, incubation for 24h with dexamethasone led also to higher GILZ TV 1 concentration (- ***p = 0.0003, n = 3; Fig. 3B). LPS stimulation did not affect GILZ TV 1 expression at all (p = n.s., n = 3; Fig. 3C).

Fig. 3
figure 3

Quantitative GILZ-mRNA expression of TV 1 in U937 cells after incubation with A hydrocortisone (10 µM) or B dexamethasone (1 µM and 10 µM) and C LPS (10 µg/ml and 100 ng/Ml] The expression was normalized to that of the housekeeping gene ß-actin using the 2 − ∆Ct formula (A *p = 0.0309, **p = 0.003, n = 3; B ***p = 0.0003, n = 3; C p = n.s., n = 3)

Full size image

Impact of hydrocortisone on GILZ transcript variant expression and the survival of septic patients

Furthermore, we wanted to confirm whether the effect of hydrocortisone on GILZ TV 1 can also be observed in septic patients. We noticed that, if hydrocortisone was given prior day eight of sepsis onset, then patients had higher expression levels of GILZ TV 1 on day 8 (Fig. 4, p = 0.023).

Fig. 4
figure 4

Effect of hydrocortisone on the concentration of GILZ TV 1 on day eight, *p = 0.023 no treatment n = 29, hydrocortisone n = 13

Full size image

Finally, we investigated whether hydrocortisone treatment affects sepsis survival in a manner dependent on GILZ-TV1 expression. Patients were stratified into two main groups: a group with low expression ratio of GILZ TV 1 relative to all transcript variants (Fig. 5A) and a group with high expression ratio (Fig. 5B). The calculated ratio of GILZ TV 1 relative to all other GILZ TVs was calculated based on the expression values on day one for GILZ TV 1 and all other GILZ TVs. Then, each group was separated into no corticosteroid treatment or hydrocortisone treatment sub-groups. Patients with low GILZ TV 1 expression quotient, below the cut-off, had similar 30-day sepsis mortality rate, regardless of glucocorticoid treatment (blue line) or no hydrocortisone treatment at all (red line) (Fig. 5A, HR = 0.549, p = 0.443, 95% CI 0.11–2.54). If the expression ratio between GILZ TV 1 relative to all transcript variants surpasses the threshold, indicating a high expression quotient, then patients who received hydrocortisone treatment (red line) had 2.38-fold greater sepsis mortality rate than patients who had high expression ratio and did not receive glucocorticoid therapy at all (Fig. 5B, p = 0.035). In multivariate Cox regression models the GILZ TV 1 expression ratio was an independent risk factor for survival independent of hydrocortisone treatment (HR = 2.303, p = 0.020; 95% CI 1.139–4.658) and septic shock (HR = 2.333, p = 0.022; 95% CI 1.129–4.820) (Supplementary Tables 6A-B). However, this effect was not independent of the SOFA score (HR = 2.1, p = 0.106, 95% CI 1.23–4.62).

Fig. 5
figure 5

K-M curves showing the 30-day survival rate of sepsis patients treated with hydrocortisone. A HR = 0.549, p = 0.443 95% 0.11–2.54. B HR = 2.38, p = 0.035, 95% CI 1.23–4.62. Numbers in brackets represent the number of dead patients in relation to total tested patient number

Full size image

Discussion

Our study demonstrates that GILZ TV 1 is associated with the 30-day mortality rate in sepsis patients. Increased expression of GILZ TV 1 seems to come along with a higher sepsis mortality rate. High expression of GILZ TV 1 on day eight is an independent risk factor for mortality, with a hazard ratio of 10.569, independent of well-known risk factors such as SOFA score, age and sex and of hydrocortisone administration in a multivariate COX regression. The expression of GILZ TV 1 seems to be upregulated via exogenous and endogenous glucocorticoids but nor by inflammatory stimulation with LPS. Additionally, in patients exhibiting a high ratio of GILZ TV1 to other transcript variants, supplemental administration of hydrocortisone appears to exacerbate the outcome further.

First, we investigated the expression of which GILZ transcript variant can be associated with sepsis survival. We discovered that GILZ TV 1 appeared to be related with sepsis survival rate, in a such way, that high GILZ TV 1 expression was in a multivariate Cox regression a dependent risk factor for mortality on day 1 with HR = 1.318 and independent risk factor for mortality on day 8 with HR = 10.569. One could speculate that patients with high GILZ TV 1 expression on day 8 might be prone for late complications such as nosocomial infections, since high expression of GILZ TV 1 on day 8 is an independent risk factor for mortality, independent of SOFA Score, age, sex and hydrocortisone treatment. In subsequent research focused solely on this transcript variant GILZ TV 1. In this context, we can speculate about the precise molecular mechanisms how and why GILZ TV 1 can be associated with the mortality. GILZ TV 1 encodes for GILZ protein isoform 1 (GILZ1) [21].

In the following paragraph, we would like to make some speculations about GILZ TV 1 mediated mechanisms. GILZ TV 1 is the longest of all GILZ isoforms and possesses an extensive N-terminus [22]. Hence the extended N-terminus of GILZ 1 could possibly be responsible for specific target binding of this isoform,[23]. The GILZ N-terminal domain is responsible for interaction with activator protein 1 (AP1) and Raf (rapidly accelerated fibrosarcoma) proteins [16, 24]. Therefore, GILZ TV1 could bind AP1 and Raf and blockade the associated pathways [25, 26], which can lead to the induction of proinflammatory cytokines [27,28,29]. In our study we found a negative correlation of GILZ TV 1 ration with IL-18, IL-23 and to a weaker extent to MCP-1 and IL-6 (Supplementary Table 7). In this regard one could speculate that inhibition of AP1, as well as Raf via the N-terminus of GILZ TV 1 might restrain the pro-inflammation significantly, further it could shift the immune balance towards anti-inflammation and it could support secondary infections [30, 31]. In this context, high expression of GILZ TV1 may contribute to lower 30-day sepsis survival rates, potentially due to its association with immune suppression which increase susceptibility to secondary infections and exacerbate mortality [32,33,34,35]. This assumption might be confirmed by the fact that especially the GILZ expression in the late phase (day 8) of sepsis seems to be relevant.

In a second step, we tried to pinpoint the mechanisms of high GILZ TV 1 expression. LPS as a pathogen-associated molecular pattern (PAMP) showed no impact on GILZ TV1 expression. Hence, the inflammation signal LPS is no regulator of GILZ TV1 expression in the tested time frame and cell line. Our observations underline that glucocorticoids remain the key inductors of GILZ. Dexamethasone and hydrocortisone led to higher GILZ TV1 expression, whereby the effect of dexamethasone was around 3-times higher than the effect of hydrocortisone. This cell culture experiments showed that GILZ expression is increased by exogenous glucocorticoids.

Besides, we could see that the quantitative expression of GILZ transcript variants was significantly increased in the time course of sepsis. As our cell culture experiments indicate no upregulation by LPS, this seems not to be caused by the infection itself. As only 26.4% of these sepsis patients were prescribed exogenous glucocorticoids (hydrocortisone), the heightened expression in the remaining 73.6% might be attributed to endogenous cortisol. This is a crucial finding, since it indicates, that endogenous glucocorticoids do play a significant role in the observed increased expression of GILZ TV 1. Endogenous glucocorticoids are synthetised and released after activation of the hypothalamic–pituitary–adrenal (HPA) axis [36]. Hence, the activation of this stress axis seems to be an endogenous regulator for GILZ TV 1 expression. Additionally, hydrocortisone is the preferred glucocorticoid in medical guidelines for the treatment of septic shock [37]. In this context, the prescription of hydrocortisone serves as an exogenous regulator for the expression of GILZ TV 1. Given our demonstration that high expression of GILZ TV 1 is associated with increased sepsis mortality, this raises concerns regarding the potential contraindication of hydrocortisone in patients with elevated GILZ TV 1 expression. Since hydrocortisone, as a glucocorticoid derivative, can impact all other GILZ TVs, an expression quotient between GILZ TV 1 and all other GILZ transcript variants (2–5) was calculated. The expression ratio cut-off value, derived for discriminating between sepsis survivors and non-survivors, was used to categorize patients into low and high GILZ TV 1 groups, with further subgrouping based on hydrocortisone prescription. Importantly, in the group with relatively high GILZ TV 1, hydrocortisone treatment was associated with 2.3-fold higher 30-day sepsis mortality rate than the sub-group with relatively high GILZ TV 1 and no hydrocortisone prescription at all. In this case, relatively high GILZ TV 1 expression quotient could serve as an indicator suggesting that patients should not be prescribed hydrocortisone treatment due to increased mortality risk. Our findings suggest that the expression ratio of GILZ TV 1 relative to other TVs could serve as a novel biomarker, indicating increased 30-day mortality risk with hydrocortisone treatment in patients exhibiting a high expression quotient. Previous research supports that hydrocortisone treatment may not be suitable for specific subgroups of sepsis patients [38,39,40].

Limitations of our study must be mentioned. Firstly, we have demonstrated in a cell culture model that upregulation of GILZ TV 1 is induced by hydrocortisone and dexamethasone. However, while we observed higher GILZ TV 1 expression levels associated with hydrocortisone prescription prior to day eight, this effect must be validated against a placebo in human studies. Furthermore, we associated a 2.3-fold increase in mortality among patients with relatively high GILZ TV 1 expression who underwent hydrocortisone therapy. However, it remains unclear whether the observed effects of high GILZ TV 1 expression are causative for higher mortality or only associations. Since high GILZ TV 1 expression on day 8 is an independent risk factor for mortality and high GILZ TV 1 ratio is also a risk factor, independent of SOFA Score, hydrocortisone or septic shock, one can speculate, that the mortality effect is probably not only due to the fact, that patients with hydrocortisone treatment are sicker, because they have septic shock and thus prone to higher mortality. It remains also unclear whether patients with relatively low GILZ TV 1 expression would benefit from glucocorticoid therapy for improved survival rates. Thus, the question arises as to whether there exists a therapeutic window for hydrocortisone treatment, wherein it should only be prescribed when the expression quotient of GILZ TV 1 falls within a specific reference range. While we noticed a trend in a specific sub-group of sepsis patients, indicating slightly higher survival rates among those with relatively low GILZ TV 1 expression, further investigation with a larger patient cohort is necessary to validate this observation. Prospective randomized studies are warranted to evaluate whether a therapeutic window exists for hydrocortisone treatment and whether the mortality impact of high GILZ TV 1 expression quotient can be mitigated with a placebo. Additionally, one must evaluate, if sepsis patients would profit only from short duration of a glucocorticoid therapy [41]. In this regard, first attempts have been started [42].

Conclusion

To summarize, the high expression of GILZ TV 1 depicts a possible biomarker for predicting the mortality rate and the responsiveness of hydrocortisone treatment in sepsis patients. It was illustrated, that high expression of GILZ TV 1 is associated with a higher 30-day mortality rate in sepsis patients and the expression seems to be regulated via exogenous, as well as endogenous glucocorticoids. Furthermore, in patients with a high expression ratio of GILZ TV 1 relative to all GILZ transcript variants, hydrocortisone treatment is associated with a 2.3-fold greater 30-day mortality rate. In this context, prospective randomized studies must assess, if the expression quotient for GILZ TV 1 can establish a therapeutic window regarding hydrocortisone prescription.

Availability of data and materials

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Ruhr University Bochum.

References

  1. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14:64–78.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Arens C, Bajwa SA, Koch C, Siegler BH, Schneck E, Hecker A, Weiterer S, Lichtenstern C, Weigand MA, Uhle F. Sepsis-induced long-term immune paralysis–results of a descriptive, explorative study. Crit Care. 2016;20:93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–75.

    Article  CAS  PubMed  Google Scholar 

  5. Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, Kyriazopoulou E, Lupse M, Monneret G, Pickkers P, Schultze JL, van der Poll T, et al. The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nat Immunol. 2024;25:19–28.

    Article  CAS  PubMed  Google Scholar 

  6. Xu C, Xu J, Lu L, Tian W, Ma J, Wu M. Identification of key genes and novel immune infiltration-associated biomarkers of sepsis. Innate Immun. 2020;26:666–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bereshchenko O, Coppo M, Bruscoli S, Biagioli M, Cimino M, Frammartino T, Sorcini D, Venanzi A, Sante M, Riccardi C. GILZ promotes production of peripherally induced treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. Cell Rep. 2014;7:464–75.

    Article  CAS  PubMed  Google Scholar 

  8. Ronchetti S, Migliorati G, Riccardi C. GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids. Front Endocrinol. 2015;6:170.

    Article  Google Scholar 

  9. Ballegeer M, Vandewalle J, Eggermont M, van Isterdael G, Dejager L, de Bus L, Decruyenaere J, Vandenbroucke RE, Libert C. Overexpression of Gilz protects mice against lethal septic peritonitis. Shock. 2019;52:208–14.

    Article  CAS  PubMed  Google Scholar 

  10. Ellouze M, Vigouroux L, Tcherakian C, Woerther P-L, Guguin A, Robert O, Surenaud M, Tran T, Calmette J, Barbin T, Perlemuter G, Cassard A-M, et al. Overexpression of GILZ in macrophages limits systemic inflammation while increasing bacterial clearance in sepsis in mice. Eur J Immunol. 2020;50:589–602.

    Article  CAS  PubMed  Google Scholar 

  11. Bruscoli S, Riccardi C, Ronchetti S. GILZ as a regulator of cell fate and inflammation. Cells. 2021;11:122.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23:3649–58.

    Article  CAS  PubMed  Google Scholar 

  13. Spiga F, Walker JJ, Terry JR, Lightman SL (2014) HPA axis-rhythms. In: Comprehensive physiology, 1273–1298

  14. Soundararajan R, Wang J, Melters D, Pearce D. Differential activities of glucocorticoid-induced leucine zipper protein isoforms. J Biol Chem. 2007;282:36303–13.

    Article  CAS  PubMed  Google Scholar 

  15. Ayroldi E, Petrillo MG, Bastianelli A, Marchetti MC, Ronchetti S, Nocentini G, Ricciotti L, Cannarile L, Riccardi C. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells. Cell Death Differ. 2015;22:118–30.

    Article  CAS  PubMed  Google Scholar 

  16. Bruscoli S, Velardi E, Di Sante M, Bereshchenko O, Venanzi A, Coppo M, Berno V, Mameli MG, Colella R, Cavaliere A, Riccardi C. Long glucocorticoid-induced leucine zipper (L-GILZ) protein interacts with ras protein pathway and contributes to spermatogenesis control. J Biol Chem. 2012;287:1242–51.

    Article  CAS  PubMed  Google Scholar 

  17. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, Hotchkiss RS, Levy MM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Unterberg M, Ehrentraut SF, Bracht T, Wolf A, Haberl H, von Busch A, Rump K, Ziehe D, Bazzi M, Thon P, Sitek B, Marcus K, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27:417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Palmowski L, Nowak H, Witowski A, Koos B, Wolf A, Weber M, Kleefisch D, Unterberg M, Haberl H, von Busch A, Ertmer C, Zarbock A, et al. Assessing SOFA score trajectories in sepsis using machine learning: a pragmatic approach to improve the accuracy of mortality prediction. PLoS ONE. 2024;19: e0300739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ziehe D, Marko B, Thon P, Rahmel T, Palmowski L, Nowak H, von Busch A, Wolf A, Witowski A, Vonheder J, Ellger B, Wappler F, et al. The aquaporin 3 polymorphism (rs17553719) is associated with sepsis survival and correlated with IL-33 secretion. Int J Mol Sci. 2024;25:1400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hoppstädter J, Diesel B, Eifler LK, Schmid T, Brüne B, Kiemer AK. Glucocorticoid-induced leucine zipper is downregulated in human alveolar macrophages upon Toll-like receptor activation. Eur J Immunol. 2012;42:1282–93.

    Article  PubMed  Google Scholar 

  22. TSC22D3 (5-Mar-2024) (retrieved on 08.05.2024). https://www.ncbi.nlm.nih.gov/gene/1831

  23. Di Marco B, Massetti M, Bruscoli S, Macchiarulo A, Di Virgilio R, Velardi E, Donato V, Migliorati G, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res. 2007;35:517–28.

    Article  PubMed  Google Scholar 

  24. Ayroldi E, Petrillo MG, Marchetti MC, Cannarile L, Ronchetti S, Ricci E, Cari L, Avenia N, Moretti S, Puxeddu E, Riccardi C. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. Cell Death Dis. 2018;9:305.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem. 2001;276:29603–10.

    Article  CAS  PubMed  Google Scholar 

  26. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol. 2002;22:7929–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66:105–43.

    Article  CAS  PubMed  Google Scholar 

  28. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–73.

    Article  CAS  PubMed  Google Scholar 

  29. Healy ZR, Zhu F, Stull JD, Konstantopoulos K. Elucidation of the signaling network of COX-2 induction in sheared chondrocytes: COX-2 is induced via a Rac/MEKK1/MKK7/JNK2/c-Jun-C/EBPβ-dependent pathway. Am J Physiol Cell Physiol. 2008;294:C1146–57.

    Article  CAS  PubMed  Google Scholar 

  30. Hoppstädter J, Kiemer AK. Glucocorticoid-induced leucine zipper (GILZ) in immuno suppression: master regulator or bystander? Oncotarget. 2015;6:38446–57.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity. 2015;42:484–98.

    Article  CAS  PubMed  Google Scholar 

  32. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk H-D. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med. 2009;180:640–8.

    Article  CAS  PubMed  Google Scholar 

  33. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15:R183.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tang BM, Herwanto V, McLean AS. Immune paralysis in sepsis: recent insights and future development. In: Vincent J-L, editor. Annual update in intensive care and emergency medicine 2018. Cham: Springer; 2018. p. 13–23.

    Chapter  Google Scholar 

  36. van den Berghe G, Téblick A, Langouche L, Gunst J. The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: gaps in current knowledge and future translational research directions. EBioMedicine. 2022;84:104284.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre P-F, Reinhart K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–24.

    Article  CAS  PubMed  Google Scholar 

  38. Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, Ashby D, Knight JC, Gordon AC. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2018;199:980–6.

    Article  Google Scholar 

  39. König R, Kolte A, Ahlers O, Oswald M, Krauss V, Roell D, Sommerfeld O, Dimopoulos G, Tsangaris I, Antoniadou E, Jaishankar N, Bogatsch H, et al. Use of IFNγ/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock. Front Immunol. 2021;12: 607217.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Schäfer ST, Gessner S, Scherag A, Rump K, Frey UH, Siffert W, Westendorf AM, Steinmann J, Peters J, Adamzik M. Hydrocortisone fails to abolish NF-κB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins/delATTG) and is associated with increased 30-day mortality in septic shock. PLoS ONE. 2014;9: e104953.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Zhang S, Chang W, Xie J, Wu Z, Yang Y, Qiu H. The efficacy, safety, and optimal regimen of corticosteroids in sepsis: a Bayesian network meta-analysis. Crit Care Explor. 2020;2: e0094.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Choi K, Park JE, Kim A, Hwang S, Bae J, Shin TG, Kim K. The DEXA-SEPSIS study protocol: a phase II randomized double-blinded controlled trial of the effect of early dexamethasone in high-risk sepsis patients. Clin Exp Emerg Med. 2022;9:246–52.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We acknowledge support from the Open Access Publication Funds of the Ruhr-Universität Bochum.

SepsisDataNet.NRW research group (alphabetical order)

Michael Adamzik1, Moritz Anft8, Thorsten Annecke5, Prof. Dr. med. Nina Babel8, Maha Bazzi1, Lars Bergmann1, Christian Bode4, Thilo Bracht9, Alexander von Busch1, Jerome M Defosse5, Stefan F. Ehrentraut4, Martin Eisennacher2, Björn Ellger7, Christian Ertmer3, Ulrich H. Frey9, Katrin Fuchs9, Helge Haberl1, Dietrich Henzler6, Daniel Kleefisch2, Thomas Köhler6, Björn Koos1, Ulrich Limper5, Katrin Marcus9, Hartmuth Nowak1, Daniel Oswald7, Christian Putensen4, Tim Rahmel1, Katharina Rump1, Jens-Christian Schewe4, Elke Schwier6, Barbara Sitek2, Matthias Unterberg1, Frank Wappler5, Katrin Willemsen1, Alexander Wolf1, Alexander Zarbock3, Birgit Zuelch1

1Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany; 2Ruhr Universität Bochum, Medizinische Fakultät, Medizinisches Proteom-Center, Bochum, Germany; 3Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Münster, Münster, Germany; 4Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Bonn, Bonn, Germany; 5Klinik für Anaesthesiologie und operative Intensivmedizin, Universität Witten/Herdecke, Krankenhaus Köln-Merheim, Köln, Germany; 6Klinik für Anaesthesiologie und operative Intensiv-, Rettungsmedizin und Schmerztherapie, Klinikum Herford, Herford, Germany; 7Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum Westfalen, Dortmund, Germany; 8Centrum für Translationale Medizin, Medizinische Klinik I, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Herne, Germany; 9Klinik für Anästhesiologie, operative Intensivmedizin, Schmerz- und Palliativmedizin, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Germany.

Funding

Open Access funding enabled and organized by Projekt DEAL. The European Regional Development Fund of the European Union (EFRE.NRW, reference number LS-1-2-012) funded the SepsisDataNet.NRW research group. The funders had no role in study design, study conduct, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892, Bochum, Germany

    Stefan Rusev, Patrick Thon, Birte Dyck, Dominik Ziehe, Tim Rahmel, Britta Marko, Lars Palmowski, Hartmuth Nowak, Lars Bergmann, Matthias Unterberg, Michael Adamzik, Björn Koos & Katharina Rump

  2. Center for Artificial Intelligence, Medical Informatics and Data Science, University Hospital Knappschaftskrankenhaus Bochum, 44892, Bochum, Germany

    Hartmuth Nowak

  3. Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum Westfalen, 44309, Dortmund, Germany

    Björn Ellger

  4. Department of Anesthesiology and Operative Intensive Care Medicine, University of Witten/Herdecke, Cologne Merheim Medical School, 51109, Cologne, Germany

    Ulrich Limper

  5. Department of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr-University Bochum, Klinikum Herford, 32049, Herford, Germany

    Elke Schwier & Dietrich Henzler

  6. Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Bonn, 53127, Bonn, Germany

    Stefan Felix Ehrentraut

Authors
  1. Stefan Rusev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Thon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birte Dyck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominik Ziehe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim Rahmel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Britta Marko
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lars Palmowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hartmuth Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Björn Ellger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ulrich Limper
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Elke Schwier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dietrich Henzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Stefan Felix Ehrentraut
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Lars Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Matthias Unterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Michael Adamzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Björn Koos
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Katharina Rump
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.R. and M.A concepted the study. S.R., P.T., B.D worked on the methods B.K provided the software T.R., D.Z., B.M validated the data S.R., K.R., M.A.L.P., performed the  analyses; investigation: B.K., M.U., K.R.; resources: M.A.; data curation: H.N., B.E., U.L., E.S., D.H., S.F.E., L.B.; writing—original draft preparation: S.R.; writing—review and editing: D.Z., L.B., K.R.; visualization:; supervision: KR and M.A.; project administration: K.R., B.K. and M.A.; funding acquisition: M.A., K.R. and B.K. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Katharina Rump.

Ethics declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Ruhr-Universität Bochum (Registration No. 5047-14).

Informed consent

Informed consent was obtained from all the subjects involved in the study.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rusev, S., Thon, P., Dyck, B. et al. High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration. Crit Care 28, 270 (2024). https://doi.org/10.1186/s13054-024-05056-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-024-05056-1

Keywords

Critical Care

ISSN: 1364-8535